4.22
Schlusskurs vom Vortag:
$4.24
Offen:
$4.24
24-Stunden-Volumen:
356.80K
Relative Volume:
0.31
Marktkapitalisierung:
$151.86M
Einnahmen:
$317.00K
Nettoeinkommen (Verlust:
$-53.47M
KGV:
-2.2328
EPS:
-1.89
Netto-Cashflow:
$-49.31M
1W Leistung:
+0.96%
1M Leistung:
+64.84%
6M Leistung:
+100.00%
1J Leistung:
+251.67%
Immuneering Corp Stock (IMRX) Company Profile
Firmenname
Immuneering Corp
Sektor
Branche
Telefon
617-500-8080
Adresse
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Vergleichen Sie IMRX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
IMRX
Immuneering Corp
|
4.22 | 150.42M | 317.00K | -53.47M | -49.31M | -1.89 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-13 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2024-03-15 | Herabstufung | Jefferies | Buy → Hold |
2024-03-15 | Bestätigt | Needham | Buy |
2024-03-15 | Herabstufung | TD Cowen | Outperform → Market Perform |
2023-12-01 | Eingeleitet | Needham | Buy |
2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
2023-04-19 | Hochstufung | Mizuho | Neutral → Buy |
2023-04-19 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
2023-03-30 | Eingeleitet | Mizuho | Neutral |
2023-02-03 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2022-07-08 | Eingeleitet | Chardan Capital Markets | Buy |
2022-04-01 | Eingeleitet | Oppenheimer | Outperform |
2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Immuneering Corp Aktie (IMRX) Neueste Nachrichten
What analysts say about Immuneering Corporation stockFree Stock Market Return Analysis - Autocar Professional
What drives Immuneering Corporation stock priceFastest-growing stock picks - jammulinksnews.com
Analysts Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $13.25 - Defense World
Is Immuneering Corporation a good long term investmentSuperior stock growth - jammulinksnews.com
What makes Immuneering Corporation stock price move sharplyTop Gaining Low Risk Assets - Newser
Why Immuneering Corporation stock attracts strong analyst attentionShort Term Profit Focus - Newser
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Revolutionary Cancer Drug Gets Patent Protection Until 2042: Clinical Data Shows 94% Survival vs 67% Standard Care - Stock Titan
Immuneering director Hausman buys IMRX stock worth $19,862 By Investing.com - Investing.com South Africa
Immuneering (IMRX) chief people officer Neufeld buys $2498 in stock By Investing.com - Investing.com South Africa
Immuneering director Hausman buys IMRX stock worth $19,862 - Investing.com
Insider Buying: Thomas Schall Acquires Additional Shares of Immu - GuruFocus
Immuneering (IMRX) Soars 10.66% on Positive Trial Data, Insider Buying - AInvest
At $3.02 Price, Immuneering Corp (IMRX) Is Sitting And Waiting - Stocksregister
Jefferies raises Immuneering price target to $3.50 from $1.50 on cancer data - Investing.com
Immuneering (IMRX) CBO Brakewood buys $4804 in shares - Investing.com
Immuneering (IMRX) director Feinberg buys $63k in shares - Investing.com
Immuneering (IMRX) CEO Zeskind buys $50k+ in shares - Investing.com
Immuneering (NASDAQ:IMRX) Receives Buy Rating from Needham & Company LLC - Defense World
Immuneering (IMRX) Target Price Raised by Mizuho Analyst | IMRX Stock News - GuruFocus
Chardan Capital Maintains Buy Rating on IMRX with $13 Price Targ - GuruFocus
Metric Deep Dive: Understanding La Rosa Holdings Corp (LRHC) Through its Ratios - DWinneX
Financial Analysis: TNL Mediagene (TNMG)’s Ratios Unveil Key Insights - DWinneX
Immuneering (IMRX) Price Target Raised by Mizuho Following Positive Trial Data | IMRX Stock News - GuruFocus
Immuneering stock price target raised to $10 at Mizuho on cancer drug data - Investing.com
Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - Investing.com India
Immuneering's Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - MENAFN.com
Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer - TipRanks
Immuneering stock rises after positive pancreatic cancer trial data - Investing.com
Immuneering (IMRX) Reports Promising Phase 2a Trial Results for Pancreatic Cancer Treatment | IMRX Stock News - GuruFocus
Pancreatic Cancer Breakthrough: New Drug Shows 94% Survival Rate vs 67% Standard Care in Phase 2a Trial - Stock Titan
Immuneering Stock Soars 25.74% on Promising Cancer Trial Results - AInvest
Immuneering Corp holds annual stockholder meeting By Investing.com - Investing.com Canada
Immuneering Corp holds annual stockholder meeting - Investing.com Australia
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - The Manila Times
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - GlobeNewswire Inc.
Two Sigma Investments LP Purchases 10,126 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World
Immuneering Co. (NASDAQ:IMRX) Stock Position Reduced by Millennium Management LLC - Defense World
Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Needham Maintains Buy Rating on IMRX with Price Target of $9.00 - GuruFocus
Full Immuneering Leadership Team Reveals Latest Pipeline Updates at Prestigious Jefferies Conference - Stock Titan
Immuneering Corporation to Present at Jefferies Global Healthcare Conference on June 5, 2025 - Nasdaq
‘Take the Plunge,’ Says Top Investor About Intel Stock - The Globe and Mail
Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.0 - GuruFocus
Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst - GuruFocus
Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst | IMRX Stock News - GuruFocus
21,432 Shares in Immuneering Co. (NASDAQ:IMRX) Acquired by Marshall Wace LLP - Defense World
Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.00 | IMRX Stock News - GuruFocus
Immuneering Corp. Reports Promising Q1 2025 Results - TipRanks
Immuneering (IMRX) Stock Rating and Price Target Update | IMRX S - GuruFocus
Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks
Finanzdaten der Immuneering Corp-Aktie (IMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):